Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$3.87 - $7.39 $5.81 Million - $11.1 Million
-1,500,000 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$4.32 - $6.43 $2.16 Million - $3.22 Million
500,000 Added 50.0%
1,500,000 $7.64 Million
Q2 2021

Aug 16, 2021

BUY
$6.33 - $9.91 $6.33 Million - $9.91 Million
1,000,000 New
1,000,000 $6.33 Million
Q3 2020

Nov 16, 2020

SELL
$6.55 - $8.83 $9.49 Million - $12.8 Million
-1,448,604 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$7.4 - $14.64 $9.69 Million - $19.2 Million
1,308,886 Added 936.81%
1,448,604 $12.1 Million
Q1 2020

May 15, 2020

BUY
$3.61 - $8.6 $504,381 - $1.2 Million
139,718 New
139,718 $1.07 Million
Q2 2019

Aug 14, 2019

SELL
$9.35 - $11.41 $8.97 Million - $10.9 Million
-959,077 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$9.5 - $19.16 $9.11 Million - $18.4 Million
959,077 New
959,077 $10.3 Million

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $55.4M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Great Point Partners LLC Portfolio

Follow Great Point Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Point Partners LLC with notifications on news.